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ABSTRACT
Objective: The purpose of this study was to evaluate the
effectiveness of CT colonography (CTC) as a triage
technique in faecal occult blood test (FOBT)-positive
screening participants.
Methods: Consecutive guaiac (G-FOBT) and immuno-
chemical (I-FOBT) FOBT-positive patients scheduled for
colonoscopy underwent CTC with iodine tagging bowel
preparation. Each CTC was read independently by two
experienced observers. Per patient sensitivity, specificity
and positive and negative predictive values (PPV and NPV)
were calculated based on double reading with different
CTC cut-off lesion sizes using segmental unblinded
colonoscopy as the reference standard. The acceptability
of the technique to patients was evaluated with
questionnaires.
Results: 302 FOBT-positive patients were included (54 G-
FOBT and 248 I-FOBT). 22 FOBT-positive patients (7%)
had a colorectal carcinoma and 211 (70%) had a lesion
>6 mm. Participants considered colonoscopy more
burdensome than CTC (p,0.05). Using a 6 mm CTC size
cut-off, per patient sensitivity for CTC was 91% (95% CI
85% to 91%) and specificity was 69% (95% CI 60% to
89%) for the detection of colonoscopy lesions >6 mm.
The PPV of CTC was 87% (95% CI 80% to 93%) and NPV
77% (95% CI 69% to 85%). Using CTC as a triage
technique in 100 FOBT-positive patients would mean that
colonoscopy could be prevented in 28 patients while
missing >10 mm lesions in 2 patients.
Conclusion: CTC with limited bowel preparation has
reasonable predictive values in an FOBT-positive popula-
tion and a higher acceptability to patients than
colonoscopy. However, due to the high prevalence of
clinically relevant lesions in FOBT-positive patients, CTC is
unlikely to be an efficient triage technique in a first round
FOBT population screening programme.
Colorectal carcinoma (CRC) is the second leading
cause of cancer deaths in the USA and many other
countries, with an approximate lifetime risk of
6%.
1 Most CRCs are assumed to develop from
benign, neoplastic adenomatous polyps.
2 Early
detection and treatment of CRCs and colorectal
adenomas could reduce mortality. Therefore, sev-
eral countries are currently investigating or have
already started a CRC screening programme using
a faecal occult blood test (FOBT). The FOBT is a
cost-effective, safe test that is acceptable to
patients and that detects more cancers at a less
advanced stage than would have presented symp-
tomatically.
3 Screening with FOBT has been
demonstrated to reduce CRC-related mortality by
14–16% over 10–18 years.
4–6
Similar to other screening tests, such as mam-
mography or PAP smear, the FOBT generates a
considerable number of false positives. In CRC
screening trials, between 0.8% and 15% of partici-
pants tested had a positive FOBT result, while
55–65% of participants with a positive FOBT result
had no CRC or adenoma.
378 As a result these
participants undergo an unnecessary colonoscopy,
which is considered by many individuals as an
investigation with significant burden and risk of
complications.
9 A potential solution to reduce this
number of unnecessary colonoscopies would be the
introduction of a triage instrument. A prerequisite
for using a triage instrument is that it has the ability
to identify correctly participants without CRC or
large polyps in those with an FOBT-positive result.
Withaveryhighnegativepredictivevalue(NPV),the
number of FOBT-positive patients receiving a
colonoscopy could be reduced while no cases with
CRC or large polyps would be missed. CT colono-
graphy (CTC) has been shown to have good per
patient test characteristics in detecting CRC and
large polyps.
10–12 Itsperpatientsensitivitywas96%in
the detection of colorectal cancer, with a sensitivity
of 93% in identifying polyps >10 mm and 86% for
polyps >6 mm. The specificity for polyps >10 mm
was 97% and for polyps >6 mm 86%.
10
Good adherence to a population screening
examination can be obtained if the offered screen-
ing method is highly acceptable to patients.
13
Previous studies have shown that CTC examina-
tions are experienced as less burdensome than
colonoscopy.
91 4The burden of the CTC may be
reduced even further if the examination is per-
formed without an extensive bowel preparation as
is required for colonoscopy.
15–17
So far, the accuracy and acceptability to patients
of CTC have only been evaluated in a screening
setting and in a high-risk population, not in FOBT
screening-positive patients as a triage technique. In
this study we evaluated the use of CTC in an
FOBT-positive screening population in terms of its
diagnostic accuracy, positive predictive value (PPV)
and NPV, and its burden, relative to colonoscopy.
METHODS
Study population
In two FOBT screening pilot studies in The
Netherlands a cohort of approximately 30 000
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test at home, of which half received a non-rehydrated guaiac
test (G-FOBT; Haemoccult II, Beckman Coulter, Fullerton,
California, USA) and the other half received a semi-quantative
immunochemical test with a cut-off level of 50 ng/ml for
positive testing (I-FOBT, OC-sensor, Eiken Chemical, Tokyo,
Japan). This was the first pilot study of CRC screening in The
Netherlands, thus invitees had not received any other CRC
screening test previously. The results of this FOBT pilot study
have been reported in detail elsewhere.
18 19 The FOBT-positive
patients scheduled to undergo colonoscopy were invited to
undergo a CTC before the colonoscopy at the Academic Medical
Centre of Amsterdam, Radboud University Nijmegen Medical
Centre or the Erasmus Medical Centre of Rotterdam, The
Netherlands. Exclusion criteria were: terminal illness, severe
psychiatric symptoms, colonoscopy or another FOBT in the
previous 2 years, examinations for research purposes with
radiation exposure in the last 12 months, iodine contrast
allergy, hyperthyroidism and pregnancy. The CTC study had
been approved by the institutional review boards of the three
institutions and written informed consent was obtained from
all participants.
CT colonography
Bowel preparation
A non-cathartic bowel preparation was used to reduce patient
discomfort. Two different bowel regimes were used. The first
153 participants received preparation 1 and the following 149
participants received preparation 2. Preparation 1 started 2 days
before CTC and consisted of ingestion of 50 ml of high-osmolar
ionic monomer meglumine ioxithalamate (Telebrix Gastro
300 mg I/ml; Guerbet, Cedex, France) with each meal ending
with 50 ml 1.5 h before CTC (total 350 ml). In addition,
patients followed a low-fibre diet for 2 days and took only
liquids on the evening and morning before CTC. Preparation 2
started 1 day before CTC with the low-fibre diet and 50 ml of
Telebrix four times (total 200 ml). The amount of ingested
contrast agent was reduced during the second half of this study
because new publications on CTC bowel preparation showed
that only 1 day of bowel preparation results in good image
quality and polyp detection.
15 16 20
CTC technique
Examinations were performed using a low dose protocol with
40 or 32 reference mAs on two 64-slice CT scanners (table 1).
Participants were scanned in the supine and prone position. A
muscle relaxant, 20 mg of butylscopolamine bromide
(Buscopan; Boehringer-Ingelheim, Ingelheim, Germany) or,
when contraindicated, 1 mg of glucagon hydrochloride
(Glucagen; Novo-Nordisk, Bagsvaerd, Denmark), was injected
immediately prior to insufflation of the colon. A flexible
balloon-tipped rectal catheter (20 French gauge) was inserted
to insufflate approximately 3 litres of CO2 gas into the colon,
using an automated insufflator (ProtoCO2l, Bracco Diagnostics,
Princeton, New York, USA). No intravenous contrast medium
was administered.
CTC image analysis
Because of the restricted bowel regime and the presence of
tagged stool, a primary 2D axial evaluation (primary window
setting 1500, 2250 HU) was carried out with 3D problem
solving for the detection of polyps. This was performed on a
workstation with specialised software (View Forum, Philips
Medical Systems, The Netherlands; Aquarius Workstation,
TeraRecon, San Matteo, California, USA). Two of seven
experienced observers (radiologists and research fellows) who
had each evaluated at least 100 CTCs verified by colonoscopy
(range 100–700 CTCs) identified lesions in the FOBT-positive
participants. The results of two observers were combined: CTC
was considered positive if at least one observer had detected a
lesion (‘‘double reading’’). This approach was used to enhance
detection as CTC is used as a triage technique for which
sensitivity and NPV are critical. The chance of missing a
relevant lesion in an FOBT positive should be minimised.
Lesions were measured at the multiplanar reformatted (MPR)
setting that showed the maximal diameter of the detected
lesion. For each lesion, the location, morphology, size and
probability (on a 5-point scale: 0, 25, 50, 75 or 100%) were
annotated. Flat polyps were defined as lesions that protrude
,2.5 mm from the adjacent mucosa.
21 Only lesions >6m m
that the observer reported with a >50% probability were
considered positive and unblinded at colonoscopy. Quality of
bowel preparation was rated on a scale from 1 (uninterpretable
images due to untagged faeces) to 5 (excellent preparation with
almost no untagged faeces) by each observer. When the CTC
was judged insufficient for evaluation by two observers, the
patient was excluded for analysis. All CTCs were also
interpreted on extracolonic findings by one of five gastrointest-
inal radiologists. Findings were classified according to the CTC
Reporting and Data System (C-RADS; for classification of
categories see table 5).
22
Colonoscopy
Within approximately 2 weeks (mean 11 days; SD 10 days)
after CTC, a colonoscopy was performed. Bowel preparation
consisted of 4 litres of polyethylene glycol electrolyte solution
(KleanPrep; Helsinn Birex Pharmaceuticals, Dublin, Ireland) or
4 litres of macrogol solution (Colofort; Laboratoires Macors,
Auxerre, France) and a clear liquid diet starting the evening
before colonoscopy. Experienced gastroenterologists, gastroen-
terology fellows and colonoscopy nurses with supervision
performed optical colonoscopy with a standard colonoscope
(Olympus, Tokyo, Japan). Sedation (midazolam, Dormicum;
Roche, Basel, Switzerland), analgesics (fentanyl, Fentanyl-
Janssen; Janssen Pharmaceuticals, Beerse, Belgium) and a muscle
relaxant (butylscopolamine bromide, Buscopan; Boehringer-
Ingelheim, Ingelheim, Germany) were commonly used in all
patients (only 2% refused sedation).
During the withdrawal of the colonoscope starting from the
caecum, the colonoscopy was videotaped and the findings of the
CTC were revealed to the colonoscopist after completing the
examination of one colonic segment. This technique is called
‘‘segmental unblinding’’ and leads to an enhanced reference
standard due to combination of CTC and colonoscopy results.
Polypsizewasestimatedbyanopenedbiopsyforcepsorbyalinear
measure probe (Olympus, Tokyo, Japan). In participants with an
incomplete colonoscopy, the colonoscopy was repeated at a later
time point. The histology of the lesion biopsies was classified as
normal, hyperplastic, adenoma (serrated, tubular, tubulovillous or
villous) or carcinoma according to the Vienna classification.
23
Advanced adenomas were defined as adenomas >10 mm, with
high-grade dysplasia or with a villous component .20%.
24
Questionnaires and participation
Six standardised questionnaires, also used in previous CTC
studies,
92 5were given to all participants. Questionnaire 1 was to
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2–5 before and just after CTC and colonoscopy, and ques-
tionnaire 6 was sent 5 weeks after colonoscopy. In question-
naire 1, participants were asked about their demographic
characteristics. In questionnaire 2 (before the CTC) and
questionnaire 4 (before colonoscopy) questions about discom-
fort of bowel preparation were asked on a 5-point scale (1=no
burden, 2=mild, 3=moderate, 4=severe or 5=extreme
burden). Questions about discomfort of the examination were
also asked after the examinations on a 5-point scale (ques-
tionnaire 3 and 5, respectively). In questionnaires 5 and 6,
participants were asked which examination or bowel prepara-
tion they found most burdensome and what examination they
would prefer in the future (answered on a 7-point scale:
1=definitely CTC to 7=definitely colonoscopy).
The participation rate was calculated for all FOBT-positive
patients who attended the outpatient clinic. Reasons for not
participating in the CTC study were noted for all FOBT-
positive subjects who attended the outpatient clinic.
Statistical analysis
The sensitivity, specificity, PPV and NPV of CTC using a CTC
lesion size cut-off of >10 mm and >6 mm were calculated on a
per patient basis for two size categories: lesions >10 mm and
lesions >6 mm found at colonoscopy. This was done for both
G-FOBT and I-FOBT at a 50 and 100 ng/ml cut-off. For our
calculations the largest polyp size measured by CTC by the two
observers was used when calculating the accuracy of CTC as a
triage technique. A patient with a matched polyp that measured
4 mm at CTC, for example, but was measured as 6 mm at
colonoscopy was considered as a false negative (using a >6m m
cut-off at CTC). Furthermore, we calculated the PPV and NPV
for different CTC cut-off values and plotted them on a graph.
Per polyp sensitivity for colonoscopy was calculated using the
false-negative lesions at colonoscopy (known after unblinding
of the CTC results). Answers on acceptability of the technique
to patients and degree of burden between CTC and colonoscopy
were compared using ordinal regression analysis. Differences in
quality of bowel preparation were tested with the x
2 test.
RESULTS
Between June 2006 and May 2008, 356 participants were
included in the CTC triage study in the participating centres. In
fig 1 a flowchart is given, presenting the numbers of participants
that gave informed consent and the numbers of excluded
participants. The data of 302 participants were complete for
analysis. The mean age of the participants was 61 years (SD 6).
Further demographic characteristics of the participants are given
in table 2. A total of 248 participants had a positive I-FOBT and
54 participants had a positive G-FOBT. This difference was due
to the differences in FOBT participation rate (I-FOBT had a
12.7% higher participation rate) and FOBT positivity rate; 2.4%
of returned tests was positive for the G-FOBT and 8.5% for the
I-FOBT with 50 ng/ml cut-off.
18 19 26
FOBT and colonoscopy results
CRC was found in 22 participants (7%); these were 14
participants in the I-FOBT group (PPV CRC 6%) and 8
participants in the G-FOBT group (PPV CRC 15%). A total of
208 lesions >10 mm were found in 142 participants (47%) and
398 lesions >6 mm in 211 participants (70%). The PPV for
lesions >10 mm in the G-FOBT-positive group was 59% vs 44%
in the I-FOBT-positive group. For lesions >6 mm the PPVs were
67 and 70% respectively. In table 3 the distribution of lesions per
histology type is given (see van Rossum et al
18 for more details
on the FOBT results). In total, 14 lesions >6 mm were found at
colonoscopy after unblinding of the CTC results, and thus were
false negative for colonoscopy. This results in a per polyp
sensitivity for colonoscopy of 96% for lesions >6 mm. In 11
participants (3.6%) bleeding followed after polypectomy during
colonoscopy for which one participant needed a hospital stay of
one night. In none of the participants did a perforation occur.
CT colonography
There were no complications at CTC. The CTCs of 10
participants were rated of insufficient quality for evaluation.
The quality of bowel preparation in both preparation groups
was not rated significantly different.
Sensitivity and specificity
When using a CTC cut-off >10 mm, the per patient sensitivity
of CTC was 82% (95% CI 74% to 89%) and the specificity was
86% (95% CI 80% to 93%) for finding lesions at colonoscopy
>10 mm. One participant with a carcinoma was missed at CTC
(sensitivity 95%) and 24 participants (17%) with an adenoma of
>10 mm were missed. Twenty-three of these adenomas
measured between 10 and 16 mm at colonoscopy and one
measured 30 mm. The missed carcinoma was a flat rectal
carcinoma that was even retrospectively not visible at CTC. In
the 24 participants with a missed adenoma, 20 of these had a
lesion that was detected at CTC but measured between 6 and
9 mm, thus being smaller than the 10 mm cut-off. In table 4
results for sensitivity and specificity are shown for I-FOBT with
50 and 100 ng/ml cut-off and for G-FOBT separately.
When using a CTC cut-off >6 mm the per patient sensitivity
of CTC was 91% (95% CI 85% to 97%) and the specificity was
69% (95% CI 60% to 78%) for finding lesions at colonoscopy
>6 mm.
Again the participant with the flat rectal carcinoma was
missed using this cut-off; 15 participants (8%) with an adenoma
of >6 mm and 6 (5%) with an adenoma of >10 mm were
missed.
Positive and negative predictive values
The PPV of CTC was 84% (95% CI 77% to 91%) for the detection
of lesions >10 mm found at colonoscopy, when using a cut-off
>10 mm at CTC. The NPV using this cut-off was 84% (95% CI
77% to 91%). Using a cut-off of >6m m ( f o r C T C a n d
colonoscopy lesions) the PPV of CTC was 87% (95% CI 80% to
93%). An NPV of 77% (95% CI 69% to 85%) corresponded to this
cut-off. Using CTC triage with a 10 mm cut-off in 100 FOBT-
positivepatientswouldmeanthatcolonoscopycouldbeprevented
in 54 patients, while missing >10 mm lesions in 9 patients. For a
Table 1 CT parameters
Philips Brilliance* Siemens SOMATOM Sensation{
Collimation 6460.625 mm 6460.6 mm
Tube voltage 120 kV 120 kV
Pitch 1.2 1.4
Reference mAs 40 mAs 32 mAs
Slice thickness 0.9 mm 1.0 mm
Rotation time 0.4 s 0.5 s
Dose modulation z-axis CARE Dose 4D{
*Brilliance, Philips Medical Systems, Best, The Netherlands.
{SOMATOM Sensation, Siemens Medical Solutions, Munich, Germany.
{CARE dose 4D incorporates x–y and z-axis modulation.
Colorectal cancer
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patients, while missing >10 mm lesions in 2 patients.
Figure 2 shows a comparison of PPV and NPV for different
CTC cut-off values. A cut-off value of 9.5 mm for CTC had a
PPV of 81% and an NPV of 86% for the detection of
colonoscopy lesions >10 mm; for 10.5 mm this was 89% and
83%. For a 5.5 mm cut-off this was 85% and 81% and for
6.5 mm this was 90% and 71%, respectively, for detection of
colonoscopy lesions >6 mm.
Extracolonic findings
Intotal 12E4extracolonicfindingswerereportedin9 participants
(2.7%). These findings had not previously been diagnosed in these
patients. See table 5 for the detected extracolonic findings
classified according to the C-RADS classification and the
additional procedures that have been performed.
Figure 1 Flowchart of faecal occult
blood test (FOBT)-positive participants.
CTC, CT colonography; NPV, negative
predictive value; PPV, positive predictive
value.
Table 2 Demographic characteristics and FOBT type
Mean age in years (SD) 61 (6)
Male/female (ratio) 187/115 (1.6:1)
Ethnicity: total number of whites 291 (97%)
Highest education level:
Primary school 20 (7%)
High school 27 (9%)
Vocational education 173 (57%)
University 77 (25%)
Not provided 5 (2%)
Nett income per month
,US$2059/.US$2059/not provided 88/131/83
FOBT:
G-FOBT 54 (18%)
I-FOBT 248 (82%)
FOBT, faecal occult blood test; G-FOBT, guaiac FOBT;
I-FOBT, immunochemical FOBT.
Table 3 Information on histology types of all removed lesions at
colonoscopy
All FOBT-positive
subjects
I-FOBT 50 ng/ml
(248 participants)
G-FOBT (54
participants)
Carcinoma 22 14 8
Adenoma 574 473 101
Hyperplastic polyp 207 182 25
Hamartoma 1 1 0
Inflammatory polyp 4 4 0
Lipoma 3 3 0
FOBT, faecal occult blood test; G-FOBT, guaiac FOBT; I-FOBT, immunochemical FOBT.
Colorectal cancer
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When comparing the two examinations, 16% of all participants
experienced the CTC examination as extremely or severely
burdensome versus 41% for the colonoscopy examination
(p,0.05; see fig 3A). For the bowel preparations, 23% of all
participants experienced the CTC bowel preparation as
extremely or severely burdensome, compared with 34% for
colonoscopy (p.0.05; see fig 3B). After 5 weeks, 85% of the
participants rated the colonoscopy as the most burdensome
examination of the two. A majority of 67% of all participants
would choose CTC as first examination after FOBT in future
screening. Of all participants that were scheduled to undergo
colonoscopy, 356 (54%) were also willing to undergo CTC (see
fig 1). The main reason for not participating in CTC triage was
that participants did not want to undergo an unnecessary
additional examination (67%).
DISCUSSION
CTC has proven to be an accurate technique for detection of
colorectal polyps and carcinomas.
10 12 This study investigated
the role of CTC with a limited bowel preparation as a triage
technique after positive FOBT in order to reduce the number of
unnecessary colonoscopies. We found a high per patient
sensitivity of CTC in the FOBT-positive subjects, especially
for finding lesions >6 mm at colonoscopy. The sensitivity for
finding lesions >10 mm was somewhat lower, which may have
resulted from the fact that most patients had only one lesion of
>10 mm but multiple lesions of >6 mm, resulting in a higher
probability of detecting at least one lesion >6 mm in a patient.
It is important to realise, however, that most polyps of 6–9 mm
are serendipitous findings because they usually do not bleed and
therefore are not the main target of an FOBT screening
programme.
When considering the usefulness of CTC as a triage
technique, one should aim for a high NPV. NPVs in this study
were fair but did not approach 100%, which would be ideal in a
triage setting. When the CTC cut-off level was decreased, the
NPV increased as result, but the number of false positives also
increased, which is not preferable. The PPVs differed somewhat
for CTC performance in the FOBT groups; the lowest PPV was
found for I-FOBT with 50 ng/ml cut-off. This difference most
probably occurred because of a difference in lesion prevalence in
the FOBT groups, which can result in a different proportion of
false positives.
One of the main reasons for performing CTC triage in FOBT-
positive subjects instead of a direct colonoscopy is that the
Table 4 Per patient sensitivity, specificity, positive and negative predictive values for CT colonography (CTC)
per lesion size category
Both FOBT I-FOBT 50 ng/ml I-FOBT 100 ng/ml G-FOBT
% Ratio (95% CI) % Ratio (95% CI) % Ratio (95% CI) % Ratio (95% CI)
Lesions >10 mm*
Sensitivity 82 116/142 (74 to 89) 80 88/110 (72 to 88) 81 69/85 (74 to 89) 88 28/32 (81 to 94)
Specificity 86 138/160 (80 to 93) 86 119/138 (79 to 93) 88 58/66 (81 to 94) 86 19/22 (80 to 93)
PPV 84 116/138 (77 to 91) 82 88/107 (75 to 90) 90 69/77 (84 to 96) 90 28/31 (85 to 96)
NPV 84 138/164 (77 to 91) 84 119/141 (77 to 92) 78 58/74 (70 to 86) 83 19/23 (75 to 90)
Lesions >6m m {
Sensitivity 91 192/211 (85 to 91) 90 157/174 (84 to 96) 90 100/111 (84 to 96) 94 34/36 (90 to 99)
Specificity 69 63/91 (60 to 89) 72 53/74 (63 to 80) 68 27/40 (57 to 77) 56 10/18 (46 to 65)
PPV 87 119/220 (80 to 93) 88 157/178 (82 to 95) 88 100/113 (82 to 95) 81 34/42 (73 to 89)
NPV 77 63/82 (69 to 85) 76 53/70 (67 to 84) 71 27/38 (62 to 80) 83 10/12 (76 to 91)
*Detection of lesions >10 mm at colonoscopy using a CTC size cut-off of >10 mm. {Detection of lesions >6 mm at colonoscopy
using a CTC size cut-off of >6 mm.
FOBT, faecal occult blood test; G-FOBT, guaiac FOBT; I-FOBT, immunochemical FOBT; NPV, negative predictive value; PPV, positive
predictive value.
Figure 2 Plot of the positive predictive
value (PPV) versus the negative predictive
value (NPV) when using different cut-off
sizes for CT colonography (CTC) for
detection of true colonoscopy lesions of
>10 mm and >6 mm. The curve shows
a plot of PPV versus 1–NPV. Results for
detection of patients with lesions on
colonoscopy of >10 mm, for cut-off sizes
for CTC lesions of >8, 9, 9.5, 10, 10.5, 11
and 12 mm are shown. Results for
detection of lesions of >6 mm are shown
for CTC cut-off sizes of 4, 5, 5.5, 6, 6.5, 7
and 8 mm.
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colonoscopy.
91 4In this study too the majority of participants
reported a lower burden of the total examination including
bowel preparation for CTC than for colonoscopy. Furthermore,
67% of the participants would prefer CTC instead of colono-
scopy as first choice for future examination.
A triage technique is only useful when the number of patients
that receive the colonoscopy will be substantially reduced. In
this study we found that if 100 FOBT-positive subjects undergo
a CTC, 46% will have to undergo a colonoscopy when using a
CTC cut-off size of 10 mm. When considering costs of the
initial management only, two different strategies are possible:
CTC as triage and subsequent colonoscopy in CTC-positive
patients or a direct colonoscopy in all FOBT-positive patients.
Using a 10 mm cut-off, CTC examination costs must not
exceed 54% of colonoscopy costs. However, this cost ratio does
not seem applicable when the current costs for these examina-
tions are considered. In a recent cost-effectiveness study by
Regge et al,
27CTC examination costs are calculated as US$665
and colonoscopy costs as US$877. Thus here the CTC costs are
76% of the colonoscopy costs. Even when using a cut-off size of
6 mm, 73% will have to undergo colonoscopy after CTC and
costs of CTC must not exceed 27% of colonoscopy costs. Hence,
from an economic perspective, the use of CTC as a triage
technique is most probably not efficient. Its apparent ineffi-
ciency resulted primarily from the high PPV of both FOBTs;
44% in those who were I-FOBT positive and 59% in those who
were G-FOBT positive. This PPV of both FOBT-positive groups
was much higher than expected considering the PPV for
adenomas and cancer in earlier studies.
5682 8However, a lower
lesion prevalence is found when using lower cut-off levels for
Table 5 Extracolonic findings in FOBT-positive participants
C-RADS
classification*
No of
participants{
Type of E4
findings{
Additional
procedures
E1 138 (42.6%) –
E2 164 (50.6%) –
E3 13 (4.0%) – Imaging: 3
E4 10 (3.1%) Aortic aneurysm: 2 Imaging: 12
Iliac aneurysm: 1 Operation: 2
Extracolonic mass: 8
Lung nodules: 2
*C-RADS classification:
22 E1 normal exam or anatomical variant; E2 clinically
unimportant finding (eg, liver or kidney cysts); E3 probably unimportant finding (eg,
indeterminate renal lesions); E4 potentially important finding (eg, aortic aneurysm,
solid mass in liver or kidney).
{Numbers represent all participants that received a CTC scan (thus also participants
that refused a colonoscopy after CTC and participants with a CTC that was of
insufficient quality for polyp detection)
{All extracolonic findings found in 9 participants.
C-RADS, CTC Reporting and Data System; FOBT, faecal occult blood test.
Figure 3 (A) Degree of burden for both
examinations overall. Participants found
the colonoscopy examination significantly
more burdensome than the colonoscopy
preparation. (B) Degree of burden from CT
colonography and colonoscopy bowel
preparations. No significant difference
was found between the degree of burden
from the colonoscopy bowel preparation
and the CT colonography bowel
preparation.
Colorectal cancer
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28 Furthermore, a few studies have reported a
decrease in lesion prevalence in successive FOBT screening
rounds.
29 30 The use of CTC might then become more cost-
efficient. Additionally, when calculating cost-efficiency, the
false-negative lesions at colonoscopy should also be considered.
In our study the per polyp sensitivity of colonoscopy was high
(96%) for lesions >6 mm.
When considering the positivity rate of the FOBT itself, this
was similar to that found in previous studies. In a review by
Hewitson et al,
5 the positivity rate of the G-FOBT varied from
0.8% to 5.3%, and other studies showed I-FOBT positivity rates
of 4.7% and 6.9%.
82 8In this study, 2.4% of returned G-FOBTs
and 8.5% of returned I-FOBTs with 50 ng/ml cut-off were
positive.
18 19 A higher positivity rate of the FOBT consequently
results in a higher number of false positives, which would make
CTC as triage more efficient. The PPV of the I-FOBT was
indeed lower than that of the G-FOBT; however, still 46% of
patients in the I-FOBT group had an adenoma or cancer
>10 mm. Therefore, CTC triage seems not to be an efficient
strategy in this first round FOBT.
In contrast to previous CTC studies, we calculated the
diagnostic accuracy by using the CTC lesion size as the cut-off:
participants will be referred for colonoscopy based on the size of
lesions measured at CTC. This method of analysing CTC as a
triage technique may give a more realistic view than the method
of matching CTC and colonoscopy polyps, and then using the
colonoscopy lesion size as the reference size for data reporting.
In this study reporting of sensitivity or specificity per lesion
histology was considered irrelevant for the evaluation of triage
with CTC, because the histology cannot be defined at CTC and
only polyp size can be used as an indicator for referral to
colonoscopy. Polyp size is an important parameter because
larger polyps (>10 mm) have a higher chance of malignant
development.
23 1 A disadvantage of this method is that
differences in measurement of lesions at CTC and colonoscopy
are not corrected by matching. Previous studies have shown
that quite large differences in measurement of CTC and
colonoscopy lesions can exist.
32 33 These differences can cause
an increase in the number of false positives and false negatives
of CTC in the setting of triage.
The graph of the predictive values for different CTC polyp
size cut-offs shows an optimal cut-off for CTC (highest PPV
and NPV) at 10 or 10.5 mm and 6 or 6.5 mm, respectively (see
fig 2). These cut-offs might be different in other settings with
another method of measurement (2D vs 3D) and different
observers.
34 35 In this study, a 2D measurement was performed
because a primary 2D read was carried out in the tagging-only
prepared CTCs. Currently, there is lack of consensus on the
optimal method of measurement; some studies showed that 2D
measurement was most accurate,
34 36 37 while others recom-
mended 3D measurement.
35 38
A known advantage of CTC compared with colonoscopy is
the lower complication rate. Previous studies reported perfora-
tion rates of 0.009% for CTC in screening participants
39 and of
0.3% for screening colonoscopy.
40 41 In this study no complica-
tions occurred during CTC, whereas 11 of those screened
reported rectal blood loss after colonoscopy. No perforations
occurred during colonoscopy. However, we must realise that
colonoscopy is not only diagnostic but also incorporates
treatment. Subjects with lesions at CTC will also have to
undergo colonoscopy and have similar risks of complications.
At CTC, extracolonic findings should be reported for ethical
reasons.
42 In this study group the number of highly relevant
findings (E4) was low (3.1%), especially when compared with
other studies with high or average risk patients, where
incidences of highly relevant findings have been reported
ranging between 9% and 23%.
43–45 The results of our study are
comparable with what was found in a large CTC screening trial
with asymptomatic patients.
11 This could be due to the low
radiation dose protocols in these studies, which might result in a
reduced visibility and detection of E4 findings.
46 The significant
extracolonic findings will inevitably lead to increased costs due
to additional examinations and treatment when CTC is used as
triage technique. Pickhardt et al showed that costs per screened
person increased by US$98.56 due to extracolonic findings in
CTC screening.
47
A potential limitation of this study is that bowel preparation
with meglumine ioxithalamate was reduced from 2 days to just
1 day after inclusion of 153 participants. This was done to
diminish the burden of the bowel preparation even more and
because newly published literature pointed out that 1 day
preparation was sufficient.
15 16 20 No differences in image quality
were seen by the CTC observers, so this change of bowel
preparation regime probably did not influence outcomes.
Another potential limitation is that all CTCs were scored by
two observers who varied during the research period. To
facilitate a quick review process, the results of both observers
were combined (double reading) and no consensus reading was
performed. Due to the double reading the number of false
negatives decreases and the sensitivity and NPV increase, at the
expense of the specificity and PPV.
48 A double read is more
costly and might not be time-efficient for screening or triage
purposes in large populations. A computer-aided detection
(CAD) system could be a solution to this problem, but on the
other hand the additional value of CAD for experienced readers
has not been proven.
49 A third potential limitation is that
selection might have occurred between participants and non-
participants in this CTC study. However, when aspects of age,
gender and lesion prevalence between the FOBT-positive
subjects in this study and the first original FOBT pilot study
are compared, no differences are observed when considering
those characteristics.
18
In conclusion, this study shows that CTC with limited
bowel preparation is unlikely to be an efficient triage
technique in a first round FOBT population screening
programme. The patient burden of the CTC was lower than
that of colonoscopy and most participants preferred CTC to
colonoscopy for future examination. However, due to the
high lesion prevalence in the FOBT-positive group and the
relatively high miss rate of relevant lesions at CTC, CTC
should not be considered as a triage technique in this specific
first round FOBT population. In further FOBT screening
rounds, lesion prevalence is possibly lower and in this
situation CTC could be more effective.
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